Deal of the Day — limited-time pharmacy picks!
Tauritmo 25mg capsule

Tauritmo 25mg capsule

Prescription requiredRx Required

Salt Composition: Midostaurin

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

4 capsule(s) in a strip

About The Product

Leukemia

Description

Tauritmo 25mg Capsule is an oral anticancer medicine with Midostaurin as an active ingredient. It belongs to the class of drugs known as multi-targeted kinase inhibitor.

It is prescribed to treat Acute Myeloid Leukemia a type of blood cancer. It works by blocking the action of specific protein responsible for the growth of cancer cells.

Thereby, it effectively controls the progression of disease. It should be taken in dose and duration as advice by the doctor.

Don't take more than the recommended dose.​

Uses

  • Treatment of (Acute Myeloid Leukemia) Blood cancer

Side Effects

Every medicine has some side effects that typically manage on their own as your body gets used to the medicine, but some people may experience severe side effects rarely. In that case, the patient should contact the doctor immediately.

Some common side effects of Tauritmo 25mg Capsule   include:

  • Febrile neutropenia
  • Nausea
  • Vomiting
  • Headache
  • Petechiae (red or purple spot caused by bleeding into the skin)
  • Musculoskeletal (bone, muscle or joint) pain
  • Nosebleeds
  • Infection
  • Increased glucose level in blood
  • Upper respiratory tract infection
  • Mucositis

How To Use

  • Doctor determines the exact dose and duration with Tauritmo 25mg Capsule as per the overall health condition of the patient. This capsule should be taken with food or after food, but at the fix time every day to get effective results.
  • Don't miss a dose or overdose on the medicine. Swallow it as a whole with a glass of water and do not crush, chew, or open it.​

How It Works

  • Tauritmo 25mg Capsule is an oral anticancer medicine with Midostaurin as an active ingredient. It belongs to the class of drugs known as multi-targeted kinase inhibitor.
  • It works by inhibiting the action of abnormal protein that promote the uncontrolled growth of cancer cells. As a result, it stops the growth of cancerous cells and slows down the progression of cancer.​​

Safety Advice

Alcohol
Avoid the consumption of alcohol while taking Tauritmo 25mg Capsule, as alcohol can reduce the effectiveness of the medicine and worsen the symptoms
Pregnancy
Do not take the Tauritmo Capsule without consulting the doctor in case of pregnancy, as it is an unsafe medicine during this period.
Breast Feeding
Breastfeeding women should discuss the potential risks and benefits of the Tauritmo with their healthcare provider before starting treatment
Driving
Tauritmo Capsule may cause side effects such as dizziness or impaired concentration, which could affect your ability to drive safely. So it's better to avoid driving or operating heavy machinery.
Kidney
Tauritmo Capsule is safe for use in kidney disease. No dosage adjustment is necessary for this Tablet.
Liver
Tauritmo Capsule is safe for use in liver disease. No dosage adjustment is necessary for this Tablet.

FAQs

This medicine is used for the treatment of blood cancer, and it helps to prevent the growth of cancer cells.

References

  • Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., ... & Döhner, H. (2017). Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. New England Journal of Medicine, 377(5), 454-464. https://pubmed.ncbi.nlm.nih.gov/28644114/
  • Gallogly, M. M., & Lazarus, H. M. (2016). Midostaurin: an emerging treatment for acute myeloid leukemia patients. Journal of blood medicine, 73-83. https://pubmed.ncbi.nlm.nih.gov/27186148/
  • Abbas, H. A., Alfayez, M., Kadia, T., Ravandi-Kashani, F., & Daver, N. (2019). Midostaurin in acute myeloid leukemia: an evidence-based review and patient selection. Cancer management and research, 8817-8828. https://pubmed.ncbi.nlm.nih.gov/31632141/
  • Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., ... & Reiter, A. (2016). Efficacy and safety of midostaurin in advanced systemic mastocytosis. New England Journal of Medicine, 374(26), 2530-2541. https://pubmed.ncbi.nlm.nih.gov/27355533/
  • Kim, E. S. (2017). Midostaurin: first global approval. Drugs, 77(11), 1251-1259.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026